CommercialCoverageMedium impact
Genetic Testing for FMR1 Variants (Including Fragile X Syndrome) (2.04.83)
Blue Shield of California·CA · Genetics, Neurology, Pediatrics +3 more·Genetic Testing
Effective date
Apr 1, 2026
We identified it
Nov 1, 2025
Summary
Blue Shield of California has updated their genetic testing policy for FMR1 variants (Fragile X syndrome), establishing specific criteria for when testing is considered medically necessary versus investigational. The policy defines covered populations including individuals with intellectual disability, developmental delay, autism spectrum disorder, and those seeking reproductive counseling with family history of FXS.
Action Required
Before April 1, 2026: Review current FMR1 genetic testing orders to ensure they meet the new medical necessity criteria. Update prior authorization requests to reference specific covered populations (intellectual disability, developmental delay, autism spectrum disorder, primary ovarian insufficiency under age 40, or family history of FXS). Document patient characteristics that align with policy criteria to support medical necessity. Claims for FMR1 testing outside these parameters will be denied as investigational.